Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP301 inhalation in acute lung injury (proof-of-concept)
2012-001863-64Phase 2Completed
- Sponsor
- APEPTICO
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of AP301 in acute lung injury (ALI) and acute pulmonary edema (APE), sponsored by APEPTICO. Primary endpoint: Change in extravascular lung water (EVLW). Started May 2012; status: completed.
02
Drugs
AP301
03
Conditions
acute lung injury (ALI)acute pulmonary edema (APE)
Beyond the preview
Go deeper on 2012-001863-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001863-64.